Recurrent oedema of the uvula in a patient with chronic spontaneous urticaria successfully treated with omalizumab

被引:1
|
作者
Pannofino, Alessandro [1 ]
机构
[1] Policoro Hosp, Operat Unit Med, Allergol & Immunol Clin, Via Salerno, I-75025 Policoro, Matera, Italy
关键词
Uvula oedema; chronic spontaneous urticaria; CSU; omalizumab; ANGIOEDEMA; DIAGNOSIS;
D O I
10.1080/09546634.2018.1550247
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Uvula oedema is a condition characterized by a sensation of a foreign body in the oropharynx and difficulty to speak; sometimes, if associated with glottis oedema, difficulty to breathe and dysphonia are also present. Urticaria is a disease characterized by itching wheals on the skin, and sometimes angioedema. Chronic urticaria is spontaneous when the etiology is unknown. Chronic urticaria may be disabling and difficult to treat, with a negative impact on the patient's quality of life. Omalizumab administration is suggested for refractory patients as add-on therapy to the antihistamines, in a third line. In Italy, omalizumab may be used for the treatment of spontaneous chronic urticaria in patients older than 12 years, refractory to antihistamines, with UAS >3 and UAS7 > 16. We describe a case of a 62-year-old woman had had recurring uvula oedema and chronic urticaria, not responder to antihistamines and oral corticosteroids. After 6 months of treatment with omalizumab and antihistamines, no urticaria recurrence was reported and no new episodes of angioedema had occurred. Our experience showed that omalizumab might be effective in patients with recurrent uvula oedema associated with urticaria.
引用
收藏
页码:8 / 9
页数:2
相关论文
共 50 条
  • [41] Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria
    Tabanlioglu-Onan, Duru
    Oktem, Ayse
    Yalcin, Basak
    Artuz, Ferda
    ASTIM ALLERJI IMMUNOLOJI, 2019, 17 (01): : 41 - 46
  • [42] Lower efficacy of omalizumab in older adults with chronic spontaneous urticaria
    Kitao, Rikuma
    Oda, Yoshiko
    Washio, Ken
    Tai, Yukimasa
    Ono, Ryusuke
    Nishigori, Chikako
    Fukunaga, Atsushi
    JOURNAL OF DERMATOLOGY, 2022, 49 (07): : 729 - 731
  • [43] Omalizumab in chronic spontaneous urticaria treatment: Real life experiences
    Engin, Burhan
    Celik, Ugur
    Birben, Aslihan Ozge
    Askin, Ozge
    Kutlubay, Zekayi
    Serdaroglu, Server
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2019, 53 (04): : 145 - 149
  • [44] Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria
    Denman, Sarah
    El-Shanaway, Tariq
    Carne, Emily
    Devlin, Lisa
    Savic, Sinisa
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 367 - 368
  • [45] Omalizumab: A Review of Its Use in Patients with Chronic Spontaneous Urticaria
    Paul L. McCormack
    Drugs, 2014, 74 : 1693 - 1699
  • [46] Omalizumab re-treatment rates in chronic spontaneous urticaria
    Khan, S.
    Sholtysek, S.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 52 (04) : 187 - 189
  • [47] Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
    Kaplan, A. P.
    Gimenez-Arnau, A. M.
    Saini, S. S.
    ALLERGY, 2017, 72 (04) : 519 - 533
  • [48] The efficacy of omalizumab therapy in chronic spontaneous urticaria: A retrospective analysis
    Turkmen, Meltem
    Coban, Melis
    Dogan, Sinan
    Uygur, Fatma
    Soylu, Ibrahim Hakki
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2019, 53 (02): : 65 - 67
  • [49] New markers to predict the response to omalizumab in chronic spontaneous urticaria
    Cosansu, Nur Cihan
    Kara, Rabia Oztas
    Yaldiz, Mahizer
    Dikicier, Bahar Sevimli
    DERMATOLOGIC THERAPY, 2022, 35 (08)
  • [50] Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero, R.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 53 (01) : 47 - 48